Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Expedition Growth Capital in connection with investment in Xensam
Mandate

Vinge advises Expedition Growth Capital in connection with investment in Xensam  

February 09, 2024 Employment and Benefits Intellectual Property M&A

Expedition Growth Capital has today announced a $40 million growth investment in the Swedish SaaS company Xensam. Vinge acted as Expedition Growth Capital’s legal advisor in connection with the investment.

Xensam is a provider of an AI-powered Software Assessment Management (SAM) platform. The platform enables its customers to understand how users interact with applications, whether SaaS or on-premise, across the entire digital infrastructure to provide a comprehensive organisational overview across hybrid environments.

Expedition Growth Capital is a London-based growth fund focused on investing in fast-growing companies.

Vinge’s team consisted of Karl Klackenberg, Clara Sohlberg and Johan Gavelin (M&A), Rebecka Målquist (IP), Olivia Onwuta (Employment) and Anna Ekdahl Roos (Transaction Support).

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025